Celcuity's gedatolisib faces July 17 FDA decision on 16.6-month PFS data
The PDUFA date tests whether a 14.7-month progression-free survival gain over fulvestrant alone converts to approval under Priority Review and Real-Time Oncology Review.
Executive Summary
- Celcuity's gedatolisib faces an FDA decision under Priority Review, with the agency due to act on a New Drug Application built on a progression-free survival result already disclosed from its pivotal trial.
- The application rests on a single cohort's efficacy data, not a fresh readout, so the regulatory question is whether that result and its safety profile support approval as filed rather than whether the drug works.
- Multiple designations preceding the filing, plus a review pathway meant to compress timelines, point to an application the agency had already signaled interest in advancing.
- The mechanism enters a class where most prior programs targeting the same pathway in this cancer have failed, so approval would mark one of few validated entries in an otherwise difficult target-indication pair.
The decision
The FDA accepted Celcuity's New Drug Application for gedatolisib in January 2026 and granted Priority Review, setting a PDUFA goal date of July 17, 2026. The application covers hormone receptor positive, HER2-negative, PIK3CA wild-type advanced breast cancer in patients who progressed on a CDK4/6 inhibitor combined with a nonsteroidal aromatase inhibitor. The submission was filed under the FDA's Real-Time Oncology Review program, intended to shorten review timelines, and follows Breakthrough Therapy and Fast Track designations gedatolisib received in 2022. CelcuityCelcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA ...Jan 20, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial showed
The NDA is built on data from the PIK3CA wild-type cohort of VIKTORIA-1 (NCT05501886), a randomized Phase 3 trial testing gedatolisib plus fulvestrant, with or without palbociclib, against fulvestrant-based standard of care in 701 patients across the United States, Argentina, Greece, Poland, Belgium and Brazil. In that cohort, gedatolisib's triplet regimen produced a median progression-free survival of 16.6 months versus 1.9 months for fulvestrant alone, a hazard ratio of 0.14 with p<0.0001. A key secondary endpoint was also met with p=0.0003, and the safety profile was described as consistent with the drug's known profile. Two other secondary endpoints, overall survival among them, have not yet been reported. NCT05501886Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886
Trial status now
VIKTORIA-1 moved to Active, not recruiting status in December 2025, with its primary completion date revised to June 30, 2026 after two earlier shifts, first from September 2024 to March 2025, then to June 2025. Enrollment stayed flat at 701 throughout, in line with the trial's original target and not a change the operational model flags as unusual. The company has said it completed enrollment of the PIK3CA mutant cohort separately, and full study completion is set for December 31, 2026, after the PDUFA date, meaning the pending FDA decision concerns only the wild-type cohort data already in hand. NCT05501886Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886
The competitive frame
Gedatolisib is a multi-target PI3K/AKT/mTOR inhibitor, distinct from single-target inhibitors of the same pathway such as Roche's inavolisib, a Phase 3 PI3K inhibitor in breast cancer that qualifies as a direct comparator on target and modality. Across PI3K-targeted programs in breast cancer, the historical Phase 3 record shows a 67% failure rate, with one of three completed trials succeeding and two terminated, and 11 distinct companies have exited programs against this target in this indication. Gedatolisib's PIK3CA wild-type result, a population where single-target PI3K inhibitors have shown less activity, sits against that record as a program that has already cleared the efficacy bar most peers in the class did not reach.
What the decision covers
A Priority Review clears in six months rather than the standard ten, and the designation itself signals the agency viewed the initial data as supporting expedited review. The decision at hand is administrative and safety-package driven at this point: whether the disclosed efficacy result, the safety data, and the chemistry, manufacturing and controls package support approval as filed, a narrower question than whether the drug is effective. CelcuityCelcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA ...Jan 20, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.